biostudies-literatureUnknown88(9)Foreman E<h4>Aims</h4>The aim of this study is to investigate the rates of hypersensitivity reactions (HSRs) in patients receiving paclitaxel chemotherapy, with and without a histamine-2 (H₂ ) antagonists.<h4>Method</h4>This prospective, multi-centre, cohort study compared patients receiving paclitaxel treated with premedication regimens containing chlorphenamine, dexamethasone and an H₂ antagonist vs patients treated without an H₂ antagonist. Rates of HSRs were described and logistic multivariable regression was used to investigate any associations with H₂ antagonist treatment, adjusting for confounding variables.<h4>Results</h4>A total of 1043 individuals were included in the study; of these, 638 (61%) patients received an H₂ antagonist and 405 (49%) were not given an H₂ antagonist. Incidence of HSR in the cohort treated with H₂ antagonists was 11.31% (n = 70) vs 9.86% (n = 41) in the cohort without. There was no statistically significant difference between the rates of HSR observed in those receiving and not receiving an H₂ antagonist (odds ratio 1.04, 95% CI 0.65, 1.66, P = .9).<h4>Conclusions</h4>Results presented within the study are consistent with other recently published evidence to suggest that H₂ antagonists do not confer any advantage as part of premedication regimens in reducing the incidence of HSR in patients treated with paclitaxel.British journal of clinical pharmacology4191-4198https://www.ebi.ac.uk/biostudies/studies/S-EPMC9545865biostudies-literatureHistamine-2 (H₂ ) antagonists can be safely removed from standard paclitaxel premedication regimens.PMC9545865Foreman EWalker AChambers PPolwart CfalseHistamine-2 (H₂ ) antagonists can be safely removed from standard paclitaxel premedication regimens.<h4>Aims</h4>The aim of this study is to investigate the rates of hypersensitivity reactions (HSRs) in patients receiving paclitaxel chemotherapy, with and without a histamine-2 (H₂ ) antagonists.<h4>Method</h4>This prospective, multi-centre, cohort study compared patients receiving paclitaxel treated with premedication regimens containing chlorphenamine, dexamethasone and an H₂ antagonist vs patients treated without an H₂ antagonist. Rates of HSRs were described and logistic multivariable regression was used to investigate any associations with H₂ antagonist treatment, adjusting for confounding variables.<h4>Results</h4>A total of 1043 individuals were included in the study; of these, 638 (61%) patients received an H₂ antagonist and 405 (49%) were not given an H₂ antagonist. Incidence of HSR in the cohort treated with H₂ antagonists was 11.31% (n = 70) vs 9.86% (n = 41) in the cohort without. There was no statistically significant difference between the rates of HSR observed in those receiving and not receiving an H₂ antagonist (odds ratio 1.04, 95% CI 0.65, 1.66, P = .9).<h4>Conclusions</h4>Results presented within the study are consistent with other recently published evidence to suggest that H₂ antagonists do not confer any advantage as part of premedication regimens in reducing the incidence of HSR in patients treated with paclitaxel.2022-01-01T00:00:00Z2022 Sep2025-04-22T01:58:21.197Z2025-04-05T20:11:06.839ZS-EPMC95458653547045210.1111/bcp.15363